


SPACS 2020

CANCER CAPITAL CORP Rank 14 of 22



RealRate

SPACS 2020

CANCER CAPITAL CORP Rank 14 of 22

The relative strengths and weaknesses of CANCER CAPITAL CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CANCER CAPITAL CORP compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 52% points. The greatest weakness of CANCER CAPITAL CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 170% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,018%, being 346% points below the market average of -672%.

Input Variable	Value in 1000 USD
Assets, Current	0.22
Assets, Non-Current	0
General And Administrative Expense	14
Liabilities, Current	302
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-16
Other Revenues	0
Professional Fees	0

Output Variable	Value in 1000 USD
Assets	0.22
Liabilities	302
Expenses	14
Revenues	0
Stockholders Equity	-302
Net Income	-29
Comprehensive Net Income	-29
Economic Capital Ratio	-1,018%

